Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy

A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trial

(2011) Thomas J. Povsic et al.   AMERICAN HEART JOURNAL

First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention

(2010) Mauricio G. Cohen et al.   CIRCULATION

Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics

(2010) Thomas Povsic et al.   THROMBOSIS AND HAEMOSTASIS

Antithrombotic Therapy for Non–ST-Segment Elevation Acute Coronary Syndromes

(2008) Robert A. Harrington et al.   CHEST

Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease

(2008) Mark Y. Chan et al.   CIRCULATION

Relationship between markers of activated coagulation, their correlation with inflammation, and association with coronary heart disease (NPHSII)

(2008) G. J. MILLER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor

(2008) M. Y. CHAN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Association between bleeding, blood transfusion, and costs among patients with non–ST-segment elevation acute coronary syndromes

(2007) Sunil V. Rao et al.   AMERICAN HEART JOURNAL